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Abstract
Background and purpose: Innovations able to maintain patient safety while reducing the amount of transfusion
add value to orthopedic procedures. Opportunities for improvement arise especially in elective procedures, as long
as room for planning is available. Although many strategies have been proposed, there is no consensus about the
most successful combination. The purpose of this investigation is to identify information to support blood
management strategies in fast-track total joint arthroplasty (TJA) pathway, to (i) support clinical decision making
according to current evidence and best practices, and (ii) identify critical issues which need further research.
Methods and materials: We identified conventional blood management strategies in elective orthopedic
procedures. We performed an electronic search about blood management strategies in fast-track TJA. We designed
tables to match every step of the former with the latter. We submitted the findings to clinicians who operate using
fast-track surgery protocols in TJA at our research hospital.
Results: Preoperative anemia detection and treatment, blood anticoagulants/aggregants consumption, transfusion
trigger, anesthetic technique, local infiltration analgesia, drainage clamping and removals, and postoperative
multimodal thromboprophylaxis are the factors which can add best value to a fast-track pathway, since they
provide significant room for planning and prediction.
Conclusion: The difference between conventional and fast-track pathways does not lie in the contents of blood
management, which are related to surgeons/surgeries, materials used and patients, but in the way these contents
are integrated into each other, since elective orthopedic procedures offer significant room for planning. Further
studies are needed to identify optimal regimens.
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Introduction
The demand for total joint arthroplasty (TJA) is going to
increase between 174 and 673% by 2030 [1, 2]. In the
USA, orthopedic procedures account for up to 10% of all
packed-red cell transfusions in a year, 39% of which are
used in TJA [3]. Blood loss can be extensive, and allogenic
blood transfusion (ABT) is commonly performed. ABTs
are associated with risks and complications [3–7]: to try
and prevent them, it is necessary to invest in increasingly
expensive safety procedures [8]. Moreover, the potential
side effects of ABTs also impact social costs [9], account-
ing for the high economic cost of ABTs.
Innovations able to maintain patient safety while reducing
the amount of ABTs therefore add value to orthopedic sur-
gery procedures, where value is defined as outcomes
achieved per money spent [10]. Opportunities for improve-
ment arise especially in elective procedures, where room for
planning is available. Indeed, experience of blood manage-
ment in 2511 elective procedures reduced the amount of
ABTs without increasing the number of recoveries and
readmissions, generating an annual saving of $ 480,000 [11].
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Blood management is a pillar of innovative health care
models such as bundled payments [12] and fast-track
pathways [13–15], as perioperative coordinated care is
associated to a better and quicker recovery [15]. Accur-
ate blood management can contribute to home dis-
charge of 85-year-old patients 3 days after surgery[16],
as well as to safely perform procedures in outpatient set-
tings [17].
Although many strategies and algorithms have been
proposed to reduce ABTs, there is no consensus about
the most successful combination, given the different
opinions over the same procedure, and the need to adapt
the procedures to the characteristics of individual pa-
tients [18–20].
The purpose of this investigation is to identify infor-
mation to support blood management strategies in fast-
track TJA pathway, to (i) support clinical decision mak-
ing according to current evidence and best practices,
and (ii) identify critical issues which need further
research.
Reviews on blood management in orthopedics surgery
[3], elective orthopedic surgery [8], total hip and knee
arthroplasty [18, 21], and lower limb joint arthroplasty
in a bundled payment [11] have been published. How-
ever, no review, to our knowledge, focuses on blood
management in fast-track orthopedic pathways, except
for general European Guidelines on perioperative venous
thromboembolism prophylaxis [22].
Such a review should be helpful in two ways: first, by
elaborating a synthesis on what has been published on
the topic; second, by pointing out which parts of the
perioperative process offer room for improvement.
Materials and methods
We proceeded in four steps.
First, we identified conventional blood management
strategies in elective orthopedic procedures, to achieve a
general road map to support the research on fast-track
innovations. Six articles addressed the perioperative ap-
proach to the topic [3, 8, 9, 18, 21, 23]. To provide a
clear roadmap and adhering to previous recommenda-
tions [24–26], the strategies were divided in preopera-
tive, intraoperative, and postoperative [27].
Second, we searched PubMed, Embase, Ebsco host,
and Cochrane reviews for blood management strategies
related to fast-track total joint arthroplasty, using the
following keywords: fast(-)track surgery, orthop(a)edics,
total joint arthroplasty, blood, blood management. After
removing duplicates and studies not related to TJA pro-
cedures, 16 articles were eligible. These were read in full
text to ensure their consistency with a fast-track TJA
pathway.
Third, we designed tables to match every step of the
perioperative process with information from the fast-
track literature. In each table, information reported in
the central column is therefore coming from conven-
tional procedures. When it was not possible to fill the
relevant column of the tables with information on fast-
track joint arthroplasty arising from the second step,
we performed a further search on the topic using
PubMed, Embase, Ebsco host and Cochrane reviews
databases, bibliographies, and articles suggested by
colleagues. These results—which are useful both for
clinical and further research—are highlighted in the
table with a *.
Fourth, we submitted the information reported in the
right column to the opinion of clinicians who operate
using fast-track surgery protocols for TJA at our hos-
pital, to (i) check whether the information was sound,
(ii) offer them opportunities for improvement, and (iii)
identify practices which they already used, as such prac-
tices may be not reported in the published literature.
We acknowledge that steps three and four prevent the
research from being entirely reproducible, which repre-
sents the main limitation of our study, but we believe
this disadvantage to be offset by the advantage of provid-
ing information which can be missed with conventional
research. We therefore opted for a narrative rather than
a systematic review. Accordingly, we have adopted four
of the six Cochrane recommendations for a systematic
review27 (Table 1).
All searches were completed by January 21st, 2019.
Results
Preoperative blood management
Preoperatively, patients are thoroughly assessed, to de-
cide whether to include them in an accelerated pathway,
to plan clinical contingencies, and to educate the pa-
tients to take active part in the process. All are key steps
in a successful fast-track design (Table 2).
Intraoperative blood management
Intraoperative management plays the most important
role in safety, blood loss minimization, and early recov-
ery (Table 3) [18].
Several studies have also investigated the role of intra-
operative intermittent pneumatic compression devices
(IPCDs) in preventing postoperative venous thrombo-
embolism (VTE), but we report them in the following
section because of their association with postoperative
pharmacological prophylaxis.
Postoperative blood management
Fifty percent of the total blood loss in TKA occurs post-
operatively [165], especially within the first 4 h (Table 4)
[166].
Postoperative thromboprophylaxis is the step of peri-
operative management which received the greatest focus
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in fast-track surgery [129]. For practical reasons, we re-
port findings about it in separate tables.
A prospective clinical study of 632 primary TJA pa-
tients evaluated the best combination between mechan-
ical treatment (compression) and pharmacological
chemoprophylaxis (aspirin and/or low molecular weight
heparin) to prevent postoperative thromboembolic
events (Table 5) [193].
The evaluation was performed answering four
questions.
According to these results, the authors advocate rou-
tine use of mobile mechanical compression devices,
which are able to prevent those VTEs and complications
associated with chemical anticoagulants. This is consist-
ent (i) with recommendations of the American Academy
of Orthopedic Surgeons and the American College of
Chest Physicians [194, 195], (ii) with a retrospective
study of 3379 patients which confirmed mechanical
treatment with IPCD to be a fast, easy, cheap, and safe
support to postoperative multimodal approach [196],
and (iii) with clinical pillars for TJA in a bundled pay-
ment paradigm [12].
With regard to accelerated pathways, the European
Guidelines on VTE prevention were formulated cross-
referencing the risk of the patient with the risk of the
procedure, adopting Caprini score as an assessment cri-
terion [22, 197] (*).
We summarize them in the following table (Table 6).
The benefits of early mobilization and the combination
between mechanical measures and aspirin are confirmed
by other studies, both in fast-track [198] (*) and in con-
ventional pathways [199].
The same guidelines underline the option, in selected pro-
cedures, to limit thromboprophylaxis treatment only to the
period of hospitalization, and suggest to extend the treat-
ment to up to 4 weeks in high-risk patients and procedures.
The first recommendation is based on a weak level of
evidence (2C), but is supported by a large prospective
study on 17,582 fast-track TJA procedures according to
which 90-day incidence of VTE after in-hospital treat-
ment was only 0.40% [53] (*). On the contrary, the sec-
ond recommendation is based on a moderate level of
evidence (2B), and supports the hypothesis of the pro-
spective study: extended treatment for LOS more than 5
days and high-risk patients is strongly recommended.
Other studies suggest warfarin-based chemoprophy-
laxis for 6 weeks after THA [200], as well as fish oil as a
cost-effective supplement to aspirin after TKA [201],
prompting for prospective studies to confirm these
suggestions.
Discussion and limitations
The purpose of this investigation was to identify infor-
mation to support blood management strategies in fast-
track TJA pathways. The investigation confirmed the
lack of comprehensive reviews on the topic, which we
divided according to recommendations in preoperative,
intraoperative, and postoperative.
The need for blood transfusions remains the most sig-
nificant predictor of a longer stay (more than 3 days)
also within accelerated pathways, occurring between
12% and 22% of THA and TKA. However, it seems not
to compromise a high patient satisfaction, a fundamental
assessment of quality in fast-track procedures. Waiting
for blood transfusions is indeed one of the main reasons
for a delay in discharge.
Identifying the reasons behind it makes it possible to
assess the best clinical and logistical solution for the pa-
tient, starting preoperatively. The need for transfusion is
associated with age, comorbidities, ASA score, and
anemia (with iron deficiency as the most common and
reversible cause). In general, a classic transfusion trigger
Table 1 Cochrane guidelines for systematic review
1 Formulation of a clear question Which procedures support the implementation of blood
management in fast-track total joint arthroplasty?
2 Exhaustive and reproducible research of all relevant information
(published and unpublished studies) concerning the question
Partly reproducible, non-exhaustive.
3 Systematic selection of eligible studies on the basis of pre-defined
inclusion criteria
All papers had to be related to fast-track pathways or
accelerated procedures, and had to be written in English
at least in the abstract.
Detailed information is reported in the PRISMA diagram
before the end of introduction.
4 Analysis of the methodological quality of included studies No.
5 Quantitative or qualitative synthesis of the information according
to the nature, complexity of the question and availability of data
To facilitate reading, qualitative and quantitative
information is synthesized and summarized in tables.
Information about fast-track procedures is matched
with every single step of the general orthopedic blood
management strategy.
6 Discussion of the reasons for agreement and inconsistency between the results of the
different studies
Yes.
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Table 2 Preoperative blood management
Content Conventional studies, guidelines, and recommendations Fast-track setting
Anemia and iron deficiency treatment
Since preoperative and postoperative anemia
are generally related, we refer to the latter in
the present section.
Anemia standards and detection
Patients undergoing TKA should meet
standard criteria regarding the minimum
preoperative Hb [28–30].
Otherwise, surgery should be postponed [29].
Recent guidelines recommend preoperative
correction of anemia and iron deficiency in all
patients with a Hb < 13 g/dL [30].
Preoperative assessment of anemic patients
should be performed between 30 and 60
days before the procedure, in order to
investigate the cause and plan the ideal
treatment [24–26, 29, 32–34].
Pre- and postoperative Hb levels (together
with the subsequent need for transfusions)
play a role on fast-track TJA postoperative
outcomes, Length of Stay (LOS) and patient
satisfaction [15, 35].
Preoperative anemia is frequently associated
with prolonged LOS, 90-day re-admission and
blood transfusions, preventing fast-track TJA
to express full value both in THA and TKA pro
cedures [31, 36] (*).
549 fast-track TJA procedures on patients
aged ≥ 85 years revealed blood-related issues
such as postoperative anemia, blood
transfusions, and mobilization to be the most
relevant medical cause of more than 4 days
LOS (27.3%), where preoperative anemia had
no significant impact.
Preoperative anemia was instead one of the
main medical causes of readmissions within
90 days, together with suspected but
disproved thromboembolic events.
Authors concluded that fast-track TJA aiming
at 3 days median LOS and discharge to home
is feasible in most patients aged ≥ 85 years,
provided attention to pre- and post-operative
anemia [16].
With regard to THA, authors show a weak but
significant correlation between post-operative
Hb and early functional recovery (6-min walk
test) in 65 year-old patients, while they did
not find any influence between the former and
other functional criteria nor quality of life [37].
Iron deficiency treatment
Iron-deficiency anemia is the main cause of
low Hb [38, 39].
This is why preoperative iron supplementation
is highly suggested in orthopedic procedures,
alone or together with intraoperative
tranexamic acid (TXA) [40, 41]. (*)
Studies report intravenous (IV) iron therapy to
be safe and dominate on oral, in particular
with patients with malabsorption such as
coeliac disease [32, 42, 43].
When using oral supplements for iron storage,
a daily dose of 100 mg elemental iron is
recommended for 2 to 6 weeks before
surgery.
When using IV iron supplementation,
requirements can be estimated using
the Ganzoni equation [44].
Studies on 882 unselected fast-track THA/TKA
patients confirmed anemia to be prevalent in
elderly patients and to be associated with
increased transfusion risk and postoperative
morbidity.
Iron deficiency is confirmed to be the most
common and reversible cause [45].
Fast-track THA non-anemic patients with iron
deficiency were supplemented with oral
highly absorbable Sideral® Forte (at least) 4
weeks before surgery. They had a smaller
decline in post-operative Hb, shorter hospital
stay and reduced blood transfusions,
generating a saving of 1763.25 € per patient.
Therefore, preoperative sucrosomial iron® is a
cost-effective solution for fast-track THA
surgery [46]. (*)
Blood thinners (antiplatelet, anticoagulant,
antithrombotic agents)
These drugs have a key role in preventing
cardiac and vascular events [47].
To normalize bleeding, they are usually
stopped a few days before surgery [8]...
... But patients at high cardiovascular risk
should not stop aspirin in the perioperative
period [48].
Given that cardiovascular disease is common
in patients planning to undergo to TKA, both
the continuation and the discontinuation of
antiplatelet therapy can be associated with
major risks, depending on patient
characteristics, severity of the procedure and
estimated time of immobilization [8, 49, 50].
The management of these medications in the
perioperative setting should be adapted to
the single patient according to cardiologist,
Preoperative use of anticoagulant agents
needs important evaluations in fast-track TJA
too [51, 52]. (*)
A study on the incidence of stroke within
30-days after 24.682 fast-track TJA found
preoperative use of anticoagulant treatment
to be the most important risk factor, together
with age ≥ 85. Anemia was also included, but
not significant.
It is therefore important to check for the use
of preoperative anticoagulants, and anemia, to
avoid cardiovascular perioperative events in
elderly patients [53]. (*)
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Table 2 Preoperative blood management (Continued)
Content Conventional studies, guidelines, and recommendations Fast-track setting
orthopedic surgeon, and anesthesiologist [18].
Transfusion protocol agreement
Although transfusion is a postoperative
intervention, establishing the trigger must be
done before surgery.
Reasons to variate transfusion practice in
orthopedic surgery are not well understood.
In case of elective surgery, the need for
allogenic transfusion was said to predictable
in 97.4% of the cases, according to (i)
preoperative anemia, (ii) perioperative blood
loss, (iii) transfusion trigger [54].
A survey on clinicians and hospitals in the UK
showed transfusion triggers after TJA to
variate between 6 to 11 g/dL, calling for
shared evidence-based guidelines to improve
practice and avoid waste [55].
This is consistent with results from a previous
international survey, according to which
transfusion triggers vary significantly among
different clinicians, hospitals and countries [56].
Systematic review on transfusion drivers in
orthopedic surgery shows low Hb and old
age to be the main predictors for the need of
transfusion, followed by surgical complexity,
low body weight, additional comorbidities
(rheumatoid arthritis, history of anemia,
diabetes, cardiovascular disease, renal failure,
or metastasis), and female sex [57].
Studies on restrictive triggers in major
orthopedic patients show transfusion rate and
deep wound infections to be respectively
reduced from 34 to 17%, and from
2.6 to 1.5% [58].
This is confirmed by a prospective study on
unilateral knee arthroplasty (UKA), which
adopted a postoperative trigger < 8.5 g/dL (or
greater in case of a symptomatic patient):
transfusion rates were reduced from 31 to
11.9%, blood waste from 60 to 1%, with no
adverse outcomes [59].
Current evidence confirms that a restrictive
trigger (Hb < 8 g/dL) is safe and cheaper3
... which is supported by the National Institute
for Health and Clinical Excellence even more
restrictive recommendations [60].
A study on fast-track TJA predictors of LOS
and patient satisfaction found:
The need for blood transfusion to be the
main predictor of a longer stay (> 3 days)
Blood transfusion to occur in 22% and 12% of
THA and TKA respectively, although it does
not compromise a high satisfaction rank (9.4
and 9.3 up to 10)
Transfusions were administered when
postoperative hematocrit level (at the first
day) was 25% less than preoperative.
Transfusions were associated with age, lack of
mobility during the first day after surgery, co-
morbidities, low Hb and increased ASA score [15].
The need for blood transfusion is a predictor
that produces significant value in accelerated
pathways such as fast-track surgery, since they
provide caregivers with useful information to
plan for treatments and beds.
Waiting for blood transfusion is indeed one of
the main reasons to delay discharge [61, 62]. (*)
Erythropoietin (EPO) EPO reduces post-operative transfusions [63] both
in THA and TKA [64–67], even in rheumatoid
arthritis patients [67], but it is associated with
adverse events such as deep venous
thrombosis (DVT), pulmonary embolism (PE),
fever, hypokalemia, urinary tract infection,
nausea, hypoxia, and vomiting in up to
5% of the population [68–70].
Moreover, it is unclear whether benefits are
not offset by costs [71].
Therefore, EPO is suggested in exceptional
conditions such as patients with strong
anemia who (i) cannot receive blood because
of red cell antibodies, (ii) refuse donation
because of religious beliefs [18, 60, 72].
The use of TXA has almost eliminated the
need for other blood conservation strategies
[73, 74], and is therefore a valuable innovation
to be applied under a fast-track pathway [75].
Preoperative autologous blood
donation (PAD)
Major concerns regarding PAD are related to
handling errors, blood infection, and poor
cost-effectiveness [76–79].
The overall benefits of PAD in primary joint
arthroplasty can outweigh the harms in
alloimmune and rare blood types patients
[8, 80].
The use of TXA has almost eliminated the
need for other blood conservation strategies
[73, 74], included PAD, which makes it a
valuable innovation under a fast-track
pathway[75].
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Table 3 Intraoperative blood management
Content Conventional studies, guide lines, and recommendations Fast-track setting
Minimally invasive surgery
(with or without navigation)
MIS techniques are believed to reduce blood loss in
TJA procedures, included the so-called tissue sparing
surgery [81–85].
Blood loss after minimally invasive TKA was compared
between using or not imageless navigation, together
with intraoperative tourniquet but no postoperative
drainage.
Blood loss was not significantly affected by the use of
imageless navigation, following which time of surgery
was a bit longer but Hb reduction and amount of
blood were similar [86].
Blood loss reduction is included in the benefits of MIS
TJA surgery.
However, a survey on fast-track TJA procedures
concludes that MIS benefits on blood loss are still
unclear [87], and more studies should be conducted to
assess whether its use in fast-track THA affects overall
patient satisfaction [88] (*).
Tourniquet Although the majority of orthopedic surgeons still
widely use it, its role remains controversial.
If tourniquet reduces intraoperative blood loss, this gain
can be offset by the amount of blood lost after its
release [89].
A meta-analysis on 30 RCTs seems to confirm its lack of
effectiveness in TKA for better clinical outcomes, less
complications and better early post-operative ROM
achieved without a tourniquet [90].
The benefits of tourniquet in TKA are also questioned
in fast-track surgery.
An RCT found knee-extension 48 h after surgery to be
reduced in 90% patients regardless to its use.
Moreover, tourniquet reduced bleeding during surgery,
but had no benefits on postoperative Hb levels, pain,
nausea, OS, or periarticular swelling.
Finally, using or not a tourniquet had no difference in
early postoperative outcomes after surgery [91].
A study on 151 fast-track TKA verified the effectiveness
of a tourniquet on post-operative bleeding and
rehabilitation together with suction drainage
application.
Suction drain was associated to lower Hb levels, higher
transfusion rate, higher pain and slower functional
recovery, while short-term tourniquet did not influence
postoperative bleeding and rehabilitation program [92]. (*)
However, a protocol for another RCT aims to verify the
effectiveness of a tourniquet on patient’s recovery after
fast-track TKA, in association to the anaesthetic
regimen.
Primary outcome is cumulative intravenous oxycodone
consumption by patient-controlled analgesia during
the first 24 postoperative hours.
Secondary outcomes include postoperative nausea and
vomiting, the length of hospital stay, the duration of
the surgery, blood loss, demand for surgical unit
resources, complications, readmissions, postoperative
knee function, range of motion, health-related quality
of life, prolonged pain, and mortality [93].
Anesthesia In order to provide guidelines for fast-track TKA, it was
conducted a survey on anaesthetic techniques [94].
With regard to blood management, it was found that
blood loss is not affected by administering regional
(RA) or general anesthesia (GA), while RA is associated
with other outcomes such as reduced post-operative
pain, length of stay and better rehabilitation [95].
RA is associated with lower thromboembolic
complications, even if—after performing a subgroup
analysis—anticoagulants were the precaution who
made the difference [96].
RA is suggested for TKA patients with comorbidities
[97], while there is no evidence enough about their
benefits on cardiovascular morbidity, DVT, and PE in
association with pharmacological thromboprophylaxis
[95].
In case of THK, the same authors did not find evidence
enough to compare the benefits of GA or RA on blood
loss [98], while others found RA to be better after
adjusting for patients’ specific comorbidities and/or
when combined with accurate transfusion prevention
[99, 100].
With regard to intraoperative blood loss, no difference
was found in performing GA (through propofol and
remifentanil) or spinal anesthesia (SA) (through
intrathecal bupivacaine)
However, GA is confirmed to dominate on SA on
relevant outcomes for a fast-track pathway, such as
early mobilization, less opioid consumption, and
reduced pain scores 6h after surgery [101].
Hypotensive epidural
anesthesia (HEA)
HEA was developed to combine the advantages of
epidural anesthesia (airway problems, reduced rate of
DVT) with the benefits of induced hypotension [102].
Although HEA’s use seems to be safe and effective, it’s
There seems to be no reason to choose or
not for HEA
according to the pathway.
Searching the literature for #hipothensive
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Table 3 Intraoperative blood management (Continued)
Content Conventional studies, guide lines, and recommendations Fast-track setting
not a first line method in TKA, while it is more spread
in THA [103–105].
epidural anaeshtesia, #hea, #arthroplasty
and #fast(-)track gave
no results.
Antifibrinolytic agents The most common antifibrinolytic agents in use are
Tranexamic Acid (TXA) and ε-aminocaproic acid (EACA)
[106–108].
TXA is more cost-effective than EACA on reducing
perioperative bleeding and transfusions [109].
Apoproptine is more effective at decreasing blood loss,
but increase the risk of cardiovascular complications.
Therefore, it has been removed from the market
[110–112].
TXA seems therefore to be the best solution.
Indeed, meta-analysis show the use of TXA in TKA to
be and effective and safe solution in reducing
blood loss [113].
A RCT proved TXA to dominate on post-operative cell
salvage both in primary THA and TKA [114], which is
confirmed by several studies, even if the ideal regime
remains controversial, and variates according to topical
(intra-articular), general (intra-venous), and amount of
administration [73, 74, 115–120].
Multiple intravenous boluses injections (pre-, intra-,
postoperatively) proved to dominate on a single
intravenous dose [121], as well as a bolus of tranexamic
acid followed by infusion was found to be more useful
than a single dose in decreasing perioperative blood
loss in patients undergoing hip surgeries: it reduced
allogenic blood transfusions without increasing risk of
thromboembolic events [122].
Intra-articular administration is a safe alternative for TKA
patients at risk for intravenous administration [123]:
moreover, one intra-articular administration is as
effective as three doses regimen in preventing blood
loss with no difference in thromboembolic
complications [124, 125].
According to another study, mixing IV and IA
administration is better than administering them alone
[126, 127].
RCTs show the high effectiveness of TXA, both with
tourniquet and without [117, 118].
Finally, there is no contraindication for its use in
patients with a history of venous
thromboembolism [128].
Tranexamic acid has been recognized as a valuable
innovation
under a bundled payment model [11] (*).
Fast-track TJA was soon declared to produce no more
complications than conventional procedures, including
thromboembolic episodes [129].
TXA is shown to reduce perioperative blood loss (and
the following need for allogenic blood transfusion) also
in accelerated recoveries and clinical pathways, without
increasing the rate of thromboembolism
[14, 92, 130, 131]. (*)
Combined intra-articular (IA) and intravenous TXA
reduced blood loss in 60 fast-track TKA patients [132].
Adding low-dose epinephrine to TXA on 100 fast-track
THA patients did not reduce blood loss during surgery,
but reduced it of 180 mL within 24 h [133]. (*)
Tranexamic acid is recognized as a valuable innovation
under a fast-track THA pathway [75].
Its effectiveness in conventional TKA had also been
largely demonstrated [114, 134], supporting it to be a
valuable innovation in fast-track TKA too.
Topical fibrin sealants (TFS) A meta-analysis on TKA suggests the administration
of intravenous TXA to dominate on TFS [135], whose
effectiveness and cost-effectiveness are debatable
[136, 137].
The eventual use of TFS in revision surgery makes them
irrelevant for fast-track pathways, which are dedicated
to primary intervention.
(Intraoperative) cell salvage A meta-analysis on 43 trials show perioperative (intra-
and post-) cell salvage to reduce blood loss in both
THA and TKA [138].
However, the study points out how more recent trials
show blood salvage benefit to be overwhelmed by
more effective innovations [139–141].
The use of TXA has almost eliminated the need for
other blood conservation strategies [73, 74], included
intraoperative blood salvation, and is therefore a
valuable innovation to be applied under a fast-track
pathway [75].
Intraoperative cell salvage is still useful to those
patients who cannot be administered TXA.
Peri/intra-articular injections Topical hemostatic vasoconstriction
Epinephrine is the agent of choice for its topical
hemostatic vasoconstriction [142].
Injections of epinephrine together with bupivacaine
just before wound closure reduced 32% of drain
output, but showed no significant reduction in
transfusion rate [143].
A synthesis on fast-track TJA clinical and organizational
aspects questioned the value of adding epinephrine
during anesthesia [129].
Adding epinephrine to TXA on 100 fast-track THA
patients did not reduce intraoperative blood loss,
but reduced it of 180 mL within 24 h [133] (*), confirming
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had been established when postoperative hematocrit
level at the first day is 25% less than preoperative, while
more recent studies found preoperative iron supplement
to be a cost-effective solution for non-anemic THA pa-
tients. However, fast-track procedures are becoming
more and more inclusive, provided that a multidisciplin-
ary management of risk factors is implemented. TKA pa-
tients aged ≥ 65 show a weak but significant association
between postoperative Hb and 6-min walk test early
after surgery, but not with other functional criteria nor
quality of life. Postoperative anemia, blood transfusions,
and lack of mobilization are the main medical causes of
delayed discharge (27.3 more than 4 days) for THA pa-
tients aged ≥ 85, while preoperative anemia is the main
medical cause of readmission of the same population
within 90 days after the intervention, together with sus-
pected (but disproved) thromboembolic events. Finally,
stroke is a recognised event which can occur after both
TKA and THA procedures: it is therefore fundamental
to check for preoperative anticoagulants to avoid cardio-
vascular perioperative complications in elderly patients.
If these precautions prove successful, fast-track pathways
realize the possibility of including older patients in major
joint replacement programs [202].
Table 3 Intraoperative blood management (Continued)
Content Conventional studies, guide lines, and recommendations Fast-track setting
Moreover, a recent study denies the effective
hemostatic role of intra-articular epinephrine
in TKA [144].
However, the combined administration of low-dose
epinephrine and tranexamic acid reduced perioperative
blood loss and inflammatory response compared with
tranexamic acid alone, with no apparent increase in
thromboembolic and other complications [145].
perioperative blood loss to be reduced by the
combination between intravenous low-dose
epinephrine and tranexamic acid.
Local infiltration analgesia (LIA)
A review over 11 RCTs shows LIA to be a safe and
efficient technique for TJA [146].
A systematic review over 27 RCTs confirmed LIA to
provide effective analgesia in TKA, either combined or
not with multimodal systemic analgesia; in contrast, LIA
provided limited additional benefit in THA when
combined with a multimodal regimen [147].
The introduction of intraoperative LIA is consistent with
blood management for its combination with TXA
proved significant benefits on postoperative Hb levels,
reduced LOS, no increase in transfusion and, therefore,
better cost-effectiveness (when compared to
perioperative autologous blood salvage and
preoperative EPO) [148].
Postoperative pain treatment is a fundamental step in
achieving early rehabilitation and reduced hospital LOS,
therefore the use of LIA is ideal in fast-track pathways
[147] (*), even more in combination with TXA, whose
benefits were discussed in the dedicated section.
Bipolar and monopolar
sealants
Bipolar sealant is a novel approach in TKA, but it
provides no significant difference in postoperative drain
output, Hb level and transfusion requirement when
compared to monopolar sealant [149–155].
As long as the cost-effectiveness of bipolar sealants
remains controversial, there is no reason to
adopt them in routine care [156].
A synthesis on fast-track TJA clinical and organizational
aspects included bipolar sealants as a means to
minimize blood loss and transfusions [129].
However, there seems to be no particular reason to
choose or not for bipolar or monopolar sealants
according to the pathway.
Searching the literature for #bipolar sealant,
#monopolar sealant and #fast(-)track gave no results.
Platelet-rich plasma (PRP) Intra-operative adoption of PRP is shown to reduce
TKA post-operative blood loss [157].
PRP is effective in wound healing, but controversial in
haemostasis [158, 159].
There seems to be no reason to choose or not for PRP
according to the pathway.
Searching the literature for #platelet rich plasma, #PRP,
#blood and #fast(-)track gave no results.
Bone wax Bone wax helps to control bleeding from bone surface
during surgical procedures [160].
Despite its recent use in TKA to reduce total blood loss
while maintaining higher Hb levels, more studies are
needed to verify its safety with regard to allergic
reactions, inflammation and foreign bodies formation
[161, 162].
There seems to be no reason to choose or not for
bone wax according to the pathway.
Searching the literature for #bone wax, #arthroplasty,
#orthopedics and #fast(-)track gave no results.
Sealing femoral tunnel A meta-analysis over 4 TKA RCTs concludes that the
use of extramedullary (EM) guide results in less blood
loss—given similar operation time—in comparison
with the intramedullary (IM) one [163]. However,
IM seems to dominate EM on TKA
survivorship [164].
There seems to be no reason to choose or not for
sealing femoral tunnel according to the pathway.
Searching the literature for #sealing femoral tunnel, #
arthroplasty and #fast(-)track gave no results.
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Intraoperatively, tranexamic acid is probably the sim-
plest, safe and cost-effective innovation also in case of
fast-track procedures, for it almost eliminated the need
for other blood conservation strategies. Its benefits in-
crease when combined (i) with local infiltration anal-
gesia, both in hip and knee replacement, as it produces a
significant reduction in postoperative Hb levels, pain
and length of stay, together with better rehabilitation
outcomes; (ii) with low-dose epinephrine in THA,
producing a reduction of 180 mL blood loss within
24 h after surgery. The benefits of minimally
invasive surgery on blood loss are still debated, and
more studies are needed to evaluate its impact on
patient satisfaction in fast-track TJA. With regard to
TKA, the use of a tourniquet reduces bleeding dur-
ing surgery, but produces no benefit on knee exten-
sion, postoperative Hb levels, pain, and nausea;
studies are evaluating its use in combination with
multimodal anaesthetic and analgesic regimens. Gen-
eral anesthesia is equivalent to spinal anesthesia with
regard to blood loss, but the former dominates the
second on several other outcomes, including early
Table 4 Postoperative blood management
Content Conventional studies, guide lines, and recommendations Fast-track setting
Postoperative anemia See Table 2.
Compression Inelastic compression bandage after TKA seems not to
reduce blood loss, but offers a slight improvement in
reducing postoperative pain and early functional
outcomes [167, 168].
According to other studies, there is no difference in
compression method [169–171].
Intermittent pneumatic compression to reduce
bleeding in (fast-track) high risk patients is
considered later, together with thromboprophylaxis.
Cryotherapy Systematic review on 13 RCTs proved cryotherapy to be
effective in reducing blood loss after TKA selected patients,
while its benefits remained controversial after THA [172].
Previous systematic review and meta-analysis over 11 TKA
studies show only slight short-lasting benefit of
cryotherapy in routine procedures [173].
Cryotherapy has been advocated as a safe and effective
strategy to improve fast-track TKA postoperative results,
acting on pain, edema, and blood loss.
Continuous cold flow device in the acute postoperative
setting did not show superiority in comparison with
traditional icing regimen.
Thus, due to the costs, it should be reserved to selected
cases [174].
Limb position Different knee flexion positions (e.g., hip elevation by 60°
combined with 60° knee flexion) have been reported to
have promising results with respect to reducing
perioperative blood loss [175–177].
Postoperative knee flexion is therefore an easy,
inexpensive, and effective method in blood loss
reduction [18].
There seems to be no reason to opt for a limb position
according to the pathway.
Searching the literature for #limb(-)position, #blood and
#fast(-)track gave 2 results, none of which consistent with
orthopedics.
Postoperative cell savage PCS effectiveness and cost-effectiveness seem to be
maximized in patients with pre-operative Hb 12–15 g/dL,
while in patients with pre-operative Hb less than 12 g/dL
it should be combined with other techniques [178].
The use of TXA has almost eliminated the need for other
blood conservation strategies [73, 74], included
postoperative blood salvation, and is therefore a valuable
innovation to be applied under a fast-track pathway [75].
Postoperative cell salvage is still useful to those patients
who cannot be administered TXA.
Drainage clamping
and removal
The introduction of drainage clamping in bilateral total
joint arthroplasty proved effective and cost-effective in
pioneer studies on TKA and THA [179, 180].
More recent studies on TKA proved its effectiveness to be
debatable [181–183], and when effective, proved
debatable intervals of administration [184–186].
Today, 3-h interval clamping proved effective in reducing
TKA postoperative Hb drop with no increase in
thromboembolic episodes and wound complications
[187], and proved to be even more effective in
combination with TXA, even if there is still need
of a major focus on duration and intervals [188, 189].
With regard to THA, 4-h drainage clamping proved
potential for routine implementation, for it reduced blood
loss and the following need of transfusion with no
significant difference on other clinical outcomes [190].
According to a RCT on 224 THA patients, intra-articular
soaking of high concentration of TXA with 2-h clamping
drainage can reduce the total blood loss and transfusion
rates in primary THA without significant increase in
postoperative thrombotic complications [191].
A prospective cohort study evaluated the safety and
feasibility of early removal of drainage tube in primary fast-
track TKA.
Wound drainage was removed within 6–12 h after surgery.
The procedure could drain the haematocele and reduce
the risk of infection, without increasing the sense of pain,
inflammatory reaction, limb swelling, and total blood loss.
Removal of drainage tube was therefore safe and feasible
within 6–12 h after surgery [192].
According to clinical expertise, drains can be avoided in
selected cases, when local conditions free of obvious
bleeding following re-established pressure ensure the
absence of the risk of hematoma.
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mobilization, amount of opioid consumption, and
pain scores 6 h after surgery.
Postoperative thromboprophylaxis is the step which
has received greater focus. The European Guidelines on
VTE prevention suggest different combinations accord-
ing to patient characteristics and procedures, underlin-
ing the benefits of early mobilization together with
mobile mechanical compression and pharmacological
treatment. Traditional icing provides a high cost-
effective benefit on several postoperative outcomes, such
as pain, edema, and blood loss, reserving more compli-
cate cryotherapy devices only to selected patients. Fi-
nally, removal of drains is safe and feasible within 6–12
h after TKA, although clinical experts question their
usefulness.
Several strategies and treatments such as hypotensive
epidural anesthesia, topical fibrin sealants, platelet-rich
plasma, sealing femoral tunnel, and limb position shows
no variation between conventional or fast-track
procedures.
A methodological limitation of the study is its partial
reproducibility, as the fast-track information achieved
from the first electronic search is integrated with infor-
mation from further searches, previous knowledge, art-
icle references, or clinical tips. This is also why the study
may not be exhaustive. However, this methodological
limitation likely compensates for the lack of information
and systematic approach on several topics in this field.
Conclusion
Many blood management strategies have been put for-
ward to support safe and cheaper orthopedic elective
TJA procedures. This article provides a roadmap to
more uniform blood management in fast-track ortho-
pedic pathways, pointing out current evidence as well as
suggestions for further research.
The difference between conventional and fast-track
pathways does not lie in the issues of blood manage-
ment, which are related to surgical procedures, materials
and patients, but in the way in which these contents are
integrated with each other, since elective orthopedic
procedures offer significant room for planning.
The more fast-track clinical studies are able to add evi-
dence, the greater the benefits for patients, providers,
and funders. The next step, therefore, is to put theory
into practice [203].
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Table 6 VTE prevention in fast-track and day-surgery
orthopedic procedures
Low VTE risk procedure High VTE risk
procedure
Low VTE risk
patient
GT
PT only in case they have to
rest in bed for more than
two days, due to particular reasons
GT + PT (LMWH/
AAS) and/or MT
High VTE risk
patient
GT + PT (LMWH/AAS)
and/or MT
GT + PT
(LMWH) + MT
General thromboprophylaxis (GT), early ambulation, optimal hydration,
pharmacological thromboprophylaxis (PT), low molecular weight heparin
(LMWH) and/or aspirin (AAS), mechanical thromboprophylaxis (MT),
intermittent pneumatic compression for high-risk of bleeding
Table 5 Mechanical and chemical thromboprophylaxis in 632 primary TJA patients
Is the incidence of readmissions resulting from VTE and
bleeding complications higher with LMWH or with
mobile compression plus ASA?
In THA, there was no difference in the frequency or readmissions
for bleeding complication (wound or systemic) between the
treatments.
In TKA, patients treated with LMWH had higher readmission
rates within 6 weeks after surgery, because of bleeding
complications, wound infection, or VTE.
Is the incidence of wound bleeding complications higher with LMWHG
or with mobile compression plus ASA?
In THA, there was higher wound bleeding complication
frequency with LMWH.
In TKA, patients treated with LMWH had a higher frequency
of wound bleeding complications or infection.
In TKA, is the frequency of systemic bleeding events and complications
related to chemoprophylaxis higher with LMWH or with mechanical
compression plus ASA?
Patients treated with LMWH had higher rates of systemic
bleeding or complications.
Is there a difference in symptomatic VTEs between LMWH and
mechanical compression plus ASA?
There was no difference between the rate of symptomatic VTEs
between the groups.
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